CYP27A1 Variant (Arg479Cys)

Most genetic tests give you abstract risk percentages. This one is different. If you carry two copies of this variant, you almost certainly have a specific disease called cerebrotendinous xanthomatosis, and that disease has a treatment that works best when started early. If you carry one copy, you do not have the disease, but your future children might if your partner is also a carrier.

The disease is rare, but the cost of missing it is high. People often go more than two decades from first symptom to diagnosis, by which point the brain damage is permanent. A simple cheek swab can settle the question in days.

What This Variant Actually Is

The CYP27A1 (cytochrome P450 family 27 subfamily A member 1) gene contains the instructions for building an enzyme called sterol 27-hydroxylase. This enzyme sits inside the energy-producing compartments of your cells (mitochondria), where it converts cholesterol into bile acids that help you digest fats. It also helps move cholesterol out of cells in your blood vessels and brain.

Arg479Cys is a single-letter typo in the gene that swaps one building block of the enzyme for another at position 479. This position sits in a region of the enzyme that holds an iron-containing chemical group (the heme group) needed to do its job. Substitutions at this exact spot have been shown to cripple the enzyme. A nearby change at the same position, Arg479Gly, has been measured to retain only about 8% of normal activity in laboratory testing of patient cells.

When the enzyme cannot do its job, cholesterol does not get properly converted to bile acids. Instead, your body builds up a related compound called cholestanol, plus unusual bile alcohols. These deposit in tendons, the lens of the eye, the brain, and arterial walls.

Cerebrotendinous Xanthomatosis Risk

Cerebrotendinous xanthomatosis (CTX) is the disease this variant causes when both copies of your CYP27A1 gene carry damaging changes. It is autosomal recessive, meaning one bad copy alone does not cause illness. Carriers feel fine. People with two bad copies develop a slow, progressive disease that touches almost every organ system.

Classic features include juvenile cataracts (often the first sign, sometimes appearing in childhood), chronic diarrhea starting in infancy, swollen yellow lumps on the Achilles tendons, and a slow neurological decline involving memory, coordination, and walking. Many people also develop early osteoporosis and premature atherosclerosis. The neurological damage is the most disabling feature, and it is the part most likely to be irreversible if treatment is delayed.

The Arg479Cys change has been reported in unrelated Sardinian families with CTX, where it appears to be a recurrent local variant. It is not common worldwide, but specific founder populations carry it at higher rates than the general population.

Why Cholesterol Levels Will Not Tell You

This is the trap that delays most CTX diagnoses by decades. People with CTX usually have normal or near-normal total cholesterol on a standard lipid panel. The problem is not too much cholesterol overall, it is cholesterol getting stuck in the wrong form and depositing in the wrong places. Tendon xanthomas with normal cholesterol are a strong clue for CTX rather than for familial hypercholesterolemia, which more commonly comes with high LDL.

If you have unexplained tendon swellings, early cataracts, chronic diarrhea since infancy, or a family member already diagnosed with CTX, a normal cholesterol panel does not rule this out. The genetic test does.

Effects in Carriers

Carrying one copy does not cause CTX. However, observational data on common low-activity variants in CYP27A1 (not Arg479Cys specifically) suggest that partial reduction of sterol 27-hydroxylase activity is associated with lower HDL cholesterol, higher cardiovascular and type 2 diabetes risk, and shorter telomeres in obese individuals. Whether single-copy Arg479Cys carriers carry any meaningful long-term cardiometabolic risk has not been directly established. The main reason to know your carrier status is reproductive: if your partner is also a CYP27A1 carrier, each child has a one-in-four chance of inheriting two damaged copies.

How Results Are Reported

Unlike a cholesterol number, this test returns one of three categorical results. Variant interpretations are based on case reports of CTX-affected families and on the functional importance of position 479 in the enzyme. There is no standardized population frequency data for this specific change.

The lab cannot tell you what your second CYP27A1 copy looks like from this single-variant test alone. If clinical suspicion of CTX is high and Arg479Cys is found on only one copy, full sequencing of CYP27A1 is the appropriate next step to look for a second damaging change.

One Test, One Result, For Life

Your genome does not change. Once you have a confirmed result, you do not need to retest. The exception is if a previous result was inconclusive or used a different lab or method, in which case repeating with a current high-quality assay can be worthwhile.

What does change over time is the clinical interpretation. As more families with this variant are described, classification can shift. If you tested years ago and the result was uncertain, it is reasonable to ask the lab to reissue an updated interpretation based on current evidence.

What to Do With a Positive Result

If you test homozygous or compound heterozygous, the next step is biochemical confirmation, not panic. A blood test for cholestanol and a urine test for bile alcohols will show whether the enzyme defect is producing the typical metabolic fingerprint. A neurologist familiar with metabolic disease, or a lipidologist, is the right person to coordinate care.

The standard treatment is chenodeoxycholic acid, a bile acid replacement that switches off the abnormal pathway and lowers cholestanol. In a study of people with CTX, this treatment improved symptoms in many patients, but those who started treatment after advanced neurological damage often continued to decline. The earlier you start, the better. Cholic acid is an alternative for those who cannot tolerate chenodeoxycholic acid. Statins are sometimes added in combination but are not a substitute for bile acid therapy.

If you test as a single-copy carrier and you are planning children, partner testing and genetic counseling are the practical next steps. If your partner is also a CYP27A1 carrier, options include prenatal testing, preimplantation testing, or simply early screening of any child for cholestanol so that treatment can start before symptoms develop.